Physician profile
Soeb Usta
NPI 1689133670
$1,656.16
in general payments reported to CMS, 2019-2025
13 companies · $541 in 2025
The $541 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $614 · 2024: $501 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,358.52 |
| Education | $297.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $495.70 | 2023-2024 | Adcetris, Padcev, Tukysa |
| Pfizer INC. | $282.29 | 2023-2025 | |
| Janssen Biotech, INC. | $272.35 | 2025 | Carvykti, Darzalex, Talvey |
| Astellas Pharma US INC | $142.00 | 2023-2024 | Xtandi |
| Shionogi INC | $111.51 | 2023 | Fetroja |
| Novartis Pharmaceuticals Corporation | $108.77 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.88 | 2024-2025 | Ninlaro, Alunbrig |
| Lilly USA, LLC | $30.48 | 2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals Lp | $30.48 | 2023-2024 | Imjudo |
| Gilead Sciences, INC. | $28.26 | 2023 | Trodelvy |
| Springworks Therapeutics, INC. | $25.87 | 2025 | Gomekli |
| Alexion Pharmaceuticals, INC. | $22.22 | 2023 | Ultomiris |
| Celgene Corporation | $18.35 | 2025 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soeb Usta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.